Report From HRS: PROTECT AF Positive For Watchman
Executive Summary
Boston Scientific is highlighting a secondary-endpoint analysis showing that the left atrial appendage closure device reduced all-cause death by 34%. The company plans to submit a PMA for the device by the end of the second quarter.
You may also be interested in...
Will Watchman Prevail With FDA? Boston Scientific’s LAA Closure Trial Raises Questions, Controversy
The PREVAIL study of Boston Scientific’s Watchman left atrial appendage (LAA) closure device was primarily positive, but will it be enough to win FDA approval for the device?
Boston Scientific Buys Atritech For Watchman Stroke Prevention Device
Boston Scientific will acquire the Watchman minimally invasive stroke-prevention device for patients with atrial fibrillation through its Jan. 19 purchase of Atritech for up to $375 million.
Panel Endorses Atritech Watchman Stroke-Prevention Device In Close Vote
An FDA advisory committee narrowly elected to recommend approval of Atritech's Watchman minimally invasive stroke-prevention device for atrial fibrillation patients, overcoming doubts about the size of the device's pivotal trial